Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Triple Negative Breast Neoplasms 163Breast Neoplasms 162Neoplasm Metastasis 157Lung Neoplasms 147Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 101Carcinoma, Transitional Cell 92Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Endometrial Neoplasms 74Carcinoma, Hepatocellular 74Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Small Cell Lung Carcinoma 39Carcinoma, Squamous Cell 39Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

pembrolizumab 1omega-N-Methylarginine 1dehydroftorafur 1atezolizumab 1Specimen Handling 1Restraint, Physical 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Repair-Deficiency Disorders × pembrolizumab × Clear all
NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Completed
12 enrolled 15 charts
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡